The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Research Technician: Next-generation sequencing”
Reference: Ref. 12-2022
Application deadline: 31/03/2022
Number of vacancies: 1
The Prostate Cancer Translational Research Group is seeking an experienced Research Technician to join the NGS team in our group.
Our group focuses on studying and testing hypothesis-based targeted therapies in prostate cancer and we are especially committed to applying the potential clinical value of our findings to clinical trials. The NGS team in our lab is formed by two wet-lab scientists and two bioinformaticians, and works in close collaboration with the rest of the multidisciplinary research group.
Find more about our research here: https://www.vhio.net/prostate-cancer-translational-research-group/
We are seeking an organized, motivated and team-oriented individual with previous experience working in a clinical/translational research laboratory either in the academic or private sector. The candidate should have previous experience in working with patient plasma/blood samples
The successful candidate will form an integral part of the scientific team and support the execution of the group’s translational research program. The position is linked to a grant from La Caixa Foundation to develop novel liquid biopsy NGS assays.
Job description:
- Processing, aliquoting and storage of blood and plasma samples from different studies.
- DNA and RNA extraction from tissue, saliva and plasma/blood samples.
- Preparation of next-generation sequencing libraries.
- Occasionally, the candidate may need to help in cell culture, cloning and transfection tasks to provide support to other projects of the group.
Requirements:
- Experience with handling human tumor samples
- Training in Good Clinical Practice for managing clinical research specimens.
- Experience in next-generation sequencing
- Experience with maintaining databases
- Exceptional attention to detail, scientific rigor, and strong organisation, troubleshooting and multitasking skills.
Additionally, the following will also be favourably considered:
- Experience with ddPCR, qPCR and FISH
- Experience with assays for isolation of circulating tumor cells and/or cell cytometry
- Experience in preparing sections from paraffin blocks
The candidate is expected to be able to communicate well in English, even if it is not his/her first language.
Additional information:
- Salary will be estimated according to profile and experience.
- The position is originally for 2 years (with an interim performance evaluation after 6 month) although it could be extended upon satisfactory review of performance.
- Start date: March-April 2022.
Application:
Potential candidates should submit a curriculum vitae, letter of intent, and at least one reference using the form below or via email to selecciorrhh@vhio.net, including the reference “Ref.12-2022” in the subject line of your email.
Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.
